MYGN

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

MoonshotScore Breakdown: 48.5/100

📰 Latest News

Myriad Genetics pioneers precision medicine through innovative genetic testing, offering crucial insights in oncology, women's health, and mental health, positioning them as a key player in personalized healthcare with a focus on hereditary cancer risk assessment and treatment optimization.

About MYGN

Myriad Genetics, Inc. is a precision medicine company specializing in genetic testing for oncology, women's health, and mental health. The company develops and commercializes a range of molecular diagnostic tests to assess disease risk and guide treatment decisions.

Myriad Genetics, Inc. Company Overview

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics, Inc. has evolved into a leading genetic testing and precision medicine company. The company focuses on developing and commercializing molecular diagnostic tests that provide critical information for personalized healthcare decisions. Myriad's initial focus was on hereditary cancer risk assessment, and it has since expanded its portfolio to include tests for women's health and mental health. Myriad's key products include the MyRisk Hereditary Cancer Test, which assesses an individual's risk for various hereditary cancers through DNA sequencing. The BRACAnalysis CDx Germline Companion Diagnostic Test helps determine appropriate therapies for patients with metastatic cancers harboring BRCA variants. The MyChoice CDx Companion Diagnostic Test assesses homologous recombination deficiency in ovarian cancer patients. Beyond oncology, Myriad offers the Foresight Carrier Screen for prospective parents and the GeneSight Psychotropic Mental Health Medication Test to aid in psychotropic drug selection. The company also provides Prolaris and EndoPredict prognostic tests for prostate and breast cancer, respectively, as well as the Prequel Prenatal Screen. Myriad Genetics has strategic collaborations with Illumina, Inc. and Intermountain Precision Genomics to enhance its testing services. The company operates both domestically in the United States and internationally.

Investment Thesis

Myriad Genetics presents a compelling investment opportunity due to its established position in the growing precision medicine market. The company's diverse portfolio of genetic tests, particularly in oncology and women's health, addresses critical needs in personalized healthcare. While currently unprofitable with a P/E of -1.19 and a negative profit margin of -48.5%, the company's high gross margin of 70.4% indicates strong pricing power and potential for future profitability as operational efficiencies improve. Growth catalysts include expanding the adoption of GeneSight in mental health and increasing the clinical utility of companion diagnostic tests like BRACAnalysis CDx and MyChoice CDx. The collaborations with Illumina and Intermountain Precision Genomics further strengthen Myriad's competitive position and innovation pipeline. As healthcare increasingly embraces personalized approaches, Myriad's expertise and established market presence position it for significant growth.

Key Financial Highlights

• Market Cap of $0.48B reflects the company's current valuation in the genetic testing market.
• Gross Margin of 70.4% demonstrates strong pricing power and efficient cost management in test development and commercialization.
• P/E Ratio of -1.19 indicates the company is currently unprofitable, but reflects potential for future earnings growth.
• Strategic collaborations with Illumina and Intermountain Precision Genomics enhance testing capabilities and market reach.
• Myriad's focus on oncology, women's health, and mental health aligns with high-growth areas in precision medicine.

Industry Context

Myriad Genetics operates within the rapidly expanding medical diagnostics and research industry, driven by increasing demand for personalized medicine and genetic testing. The industry is characterized by technological advancements, evolving regulatory landscapes, and intense competition. The market for genetic testing is projected to continue growing at a significant rate, fueled by advancements in DNA sequencing technologies and the increasing prevalence of genetic disorders and cancers. Myriad competes with companies like AMN (AMN Healthcare), CDNA (CareDx), CSTL (Castlight Health), DNA (Ginkgo Bioworks), and DRIO (DarioHealth Corp.) all vying for market share in various segments of the diagnostics and precision medicine space.

Quarterly Financial Summary

Source: Company filings. Data may be delayed.

Growth Opportunities

• Expanding GeneSight Adoption in Mental Health: The GeneSight Psychotropic Mental Health Medication Test represents a significant growth opportunity for Myriad. With the increasing prevalence of mental health disorders and the challenges of finding effective treatments, GeneSight offers a valuable tool for clinicians. By increasing awareness and demonstrating the clinical and economic benefits of GeneSight, Myriad can drive adoption among psychiatrists and primary care physicians. The market for pharmacogenomic testing in mental health is estimated to reach several billion dollars in the coming years.
• Increasing Clinical Utility of Companion Diagnostic Tests: Myriad's BRACAnalysis CDx and MyChoice CDx companion diagnostic tests play a crucial role in guiding treatment decisions for cancer patients. By expanding the approved indications for these tests and demonstrating their value in improving patient outcomes, Myriad can drive increased utilization. The market for companion diagnostics is growing rapidly, driven by the increasing availability of targeted therapies and the need for personalized treatment strategies.
• Strategic Partnerships and Collaborations: Myriad's collaborations with Illumina and Intermountain Precision Genomics provide access to advanced technologies and expanded market reach. By forging additional strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers, Myriad can accelerate the development and commercialization of new genetic tests and expand its market presence. These partnerships can also provide access to valuable data and insights that can inform product development and marketing strategies.
• Geographic Expansion: While Myriad has a presence in the United States and internationally, there is significant opportunity to expand its geographic reach. By targeting key international markets with high unmet needs for genetic testing, Myriad can drive revenue growth and diversify its customer base. This expansion can be achieved through direct sales, partnerships with local distributors, and strategic acquisitions.
• Development of Novel Genetic Tests: Myriad has a strong track record of developing and commercializing innovative genetic tests. By investing in research and development and leveraging its expertise in genomics and bioinformatics, Myriad can continue to develop novel tests that address unmet needs in oncology, women's health, and other areas. This includes exploring new applications of genetic testing, such as early disease detection and personalized prevention strategies.

Competitive Advantages

• Proprietary genetic tests with patent protection.
• Established brand reputation and market leadership.
• Extensive clinical data supporting test utility.
• Strong relationships with healthcare providers.
• Strategic collaborations with key industry players.

Strengths

• Diverse portfolio of genetic tests.
• Established market presence in oncology and women's health.
• Strong brand reputation.
• Proprietary technology and intellectual property.

Weaknesses

• Currently unprofitable.
• High beta of 1.89 indicates high volatility.
• Negative profit margin of -48.5%.
• Reliance on reimbursement from insurance companies.

Opportunities

• Expanding adoption of GeneSight in mental health.
• Increasing clinical utility of companion diagnostic tests.
• Strategic partnerships and collaborations.
• Geographic expansion.

Threats

• Competition from other genetic testing companies.
• Changes in reimbursement policies.
• Technological advancements that could render existing tests obsolete.
• Regulatory hurdles.

What MYGN Does

• Develop and commercialize genetic tests for oncology.
• Offer tests to assess hereditary cancer risks.
• Provide diagnostic tests for women's health.
• Offer genetic testing solutions for mental health.
• Provide tumor profiling services to guide cancer treatment.
• Offer prenatal screening tests.
• Provide carrier screening for inherited conditions.

Business Model

• Develop and sell proprietary genetic tests.
• Generate revenue through test orders from healthcare providers.
• Receive reimbursement from insurance companies and patients.
• Establish strategic collaborations to expand test offerings and market reach.

Key Customers

• Oncologists and other cancer specialists.
• Obstetricians and gynecologists.
• Psychiatrists and other mental health professionals.
• Hospitals and clinics.
• Pharmaceutical companies.

Competitors

• AMN Healthcare (AMN): Provides healthcare staffing and workforce solutions.
• CareDx (CDNA): Focuses on transplant diagnostics.
• Castlight Health (CSTL): Offers healthcare navigation and benefits platform.
• Ginkgo Bioworks (DNA): Specializes in synthetic biology and biomanufacturing.
• DarioHealth Corp. (DRIO): Provides digital health solutions for chronic conditions.

Catalysts

• Ongoing: Expansion of GeneSight into new mental health indications.
• Ongoing: Increasing adoption of MyRisk hereditary cancer testing.
• Upcoming: Potential new partnerships with pharmaceutical companies for companion diagnostics.
• Upcoming: Positive clinical trial results for new genetic tests in development.

Risks

• Ongoing: Reimbursement pressures from insurance providers.
• Potential: Increased competition from other genetic testing companies.
• Potential: Unfavorable regulatory changes.
• Ongoing: Economic downturn affecting healthcare spending.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Medical - Diagnostics & Research

Browse More

Next Steps